Halozyme Therapeutics has expanded its portfolio of drug delivery technologies for a second time in a few months with the acquisition of Surf Bio and its subcutaneous injection platform. The ...

Recently, a pharmaceutical company came to the antibody-discovery specialist, Abveris, with a serious problem. The pharmaceutical company had tried and failed to develop a monoclonal antibody for an ...